NCT01331122撤回1 期
A Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's Disease
Chelsea Therapeutics2 个研究点 分布在 2 个国家开始时间: 2012年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 试验地点
- 2
- 主要终点
- Evaluate the safety of droxidopa as measured by the incidence, relatedness, and severity of adverse events.
研究概览
简要总结
Freezing of Gait (FoG) is a class of symptoms that occur in Parkinson's patients. Also called motor blocks, FoG is characterized by a sudden inability to move the lower extremities which usually lasts less than 10 seconds. The exact pathophysiology of FoG is poorly understood, but treatment with levodopa appears to improve FoG observed in the off-state. As Parkinson's patients progress in severity, FoG in the on-state can increase in frequency and appears to be resistant to dopaminergic therapies. There is additional evidence that norepinephrine as well as dopaminergic systems may be involved in FoG.
Droxidopa has has been approved for use in Japan since 1989 for treatment of frozen gait or dizziness associated with Parkinson's Disease. This study is to further explore the safety and efficacy of droxidopa in this indication.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients, aged at least 30 years;
- •Diagnosed with probable levodopa-responsive idiopathic Parkinson's Disease , and receiving levodopa. Other Parkinson's Disease medications can also be used.
- •At least 3 months incidence of typical freezing of gait (FOG) symptoms, occurring while levodopa is otherwise providing an "on" mobility state (including at least one of the following FOG patterns: start hesitancy, freezing at making turns or when passing through a doorway, spontaneous freezing during continued walking, or freezing of gait related to a simultaneous mental or physical activity).
- •Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care
- •On a stable dose of carbidopa, alone or with other Parkinson's medication, providing a range of carbidopa between 100mg and 400mg daily
排除标准
- •Taking direct acting vasoconstricting agent (i.e. ephedrine or midodrine). Patients taking vasoconstrictor agents such as ephedrine or midodrine must stop taking these drugs at least 2 days or 5 half-lives (whichever is longer) prior to their baseline visit;
- •Taking more than one anti-hypertensive medication for the treatment of high blood pressure. Short acting anti-hypertensive medication taken at night to prevent supine hypertension will be allowed.
- •Have changed dose or frequency of Parkinson's medication within 2 weeks of baseline
- •Known or suspected alcohol or substance abuse within 1 year
- •Sustained hypertension (BP greater than 140/90 mmHg in the sitting position)
- •Symptomatic coronary artery disease, severe congestive heart failure
- •Women who are pregnant, lactating, or plan to become pregnant during the course of this study;
- •Women of child bearing potential (WOCP) who are not using two methods of contraception (at least one barrier: i.e. condom) with their partner.
- •Male patients who are sexually active with a woman of child bearing potential (WOCP) and not using two methods of contraception (at least one barrier: i.e. condom)
- •Untreated closed angle glaucoma, or treated closed angle glaucoma that in the opinion of an ophthalmologist would cause increased risk to the patient;
- •Active (last 6 months) atrial fibrillation or, in the investigator's opinion, any other significant cardiac arrhythmia that should preclude the patient from this trial;
- •History of myocardial infarction or unstable angina
- •Diabetes insipidus, insulin dependent diabetes mellitus, or diabetic neuropathy;
- •In the investigator's opinion, any other significant systemic illness;
- •Known or suspected malignancy (other than basal cell carcinoma);
- •Known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug;
- •Any major surgical procedure within 30 days of the baseline visit;
- •Currently receiving any investigational drug or have received an investigational drug within 30 days of the baseline visit;
- •In the investigator's opinion, clinically significant abnormalities on clinical examination or laboratory testing that should preclude the patient from this trial;
- •Patient has only lower body Parkinson's Disease
- •In the investigators opinion, freezing of gait is attributable to previous stroke
研究组 & 干预措施
droxidopa
Experimental
Northera (2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid L-DOPS L-threo-dihydroxyphenylserine Droxidopa SM-5688
干预措施: droxidopa (Drug)
placebo
Placebo Comparator
placebo
干预措施: droxidopa (Drug)
结局指标
主要结局
Evaluate the safety of droxidopa as measured by the incidence, relatedness, and severity of adverse events.
时间窗: 18 Weeks
次要结局
- Evaluate the effect of droxidopa on freezing of gait symptoms using the Freezing of Gait Questionnaire(18 Weeks)
- Evaluate the efficacy of droxidopa in the treatment of freezing of gait by using the Observed Freezing of Gait Rating (OFGR) scale(18 Weeks)
- Evaluate the effect of droxidopa on signs and symptoms associated with Parkinson's Disease utilizing the composite scores of the Unified Parkinson's Disease Rating Scale(18 Weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Freezing of Gait: Clinical, Cognitive, and Imaging FeaturesParkinson DiseaseNCT02387281Emory University60
招募中
不适用
DetectFoG : Detection of Gait Freezing Episodes in Parkinsonian Patients Using Inertial Measurement UnitsParkinson DiseaseNCT05822258Rennes University Hospital20
招募中
不适用
Exploring the Possible Beneficial Impact of Non-invasive and Invasive Neuromodulation on Freezing of Gait in Parkinson's Disease During Different Ambulatory Complexities: An Electrophysiological and fMRI StudyTranscranial Direct Current StimulationNCT06505460China Medical University Hospital20
终止
不适用
Assisted Device for Freezing in Parkinson DiseaseParkinson DiseaseNCT02317289University Hospital, Montpellier26
Unknown
不适用
Working on Asymmetry in Parkinson's DiseaseParkinson's DiseaseNCT02051556Neuromed IRCCS42